+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

PIK3CA H1047R -induced paradoxical ERK activation results in resistance to BRAF V600E specific inhibitors in BRAF V600E PIK3CA H1047R double mutant thyroid tumors

PIK3CA H1047R -induced paradoxical ERK activation results in resistance to BRAF V600E specific inhibitors in BRAF V600E PIK3CA H1047R double mutant thyroid tumors

Oncotarget 8(61): 103207-103222

Thyroid carcinomas are the most prevalent endocrine cancers. The BRAFV600E mutation is found in 40% of the papillary type and 25% of the anaplastic type. BRAFV600E inhibitors have shown great success in melanoma but, they have been, to date, less successful in thyroid cancer. About 50% of anaplastic thyroid carcinomas present mutations/amplification of the phosphatidylinositol 3' kinase. Here we propose to investigate if the hyper activation of that pathway could influence the response to BRAFV600E specific inhibitors. To test this, we used two mouse models of thyroid cancer. Single mutant (BRAFV600E) mice responded to BRAFV600E-specific inhibition (PLX-4720), while double mutant mice (BRAFV600E; PIK3CAH1047R) showed resistance and even signs of aggravation. This resistance was abrogated by combination with a phosphoinositide 3-kinase inhibitor. At the molecular level, we showed that this resistance was concomitant to a paradoxical activation of the MAP-Kinase pathway, which could be overturned by phosphoinositide 3-kinase inhibition in vivo in our mouse model and in vitro in human double mutant cell lines. In conclusion, we reveal a phosphoinositide 3-kinase driven, paradoxical MAP-Kinase pathway activation as mechanism for resistance to BRAFV600E specific inhibitors in a clinically relevant mouse model of thyroid cancer.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 065409194

Download citation: RISBibTeXText

PMID: 29262556

Related references

Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Research 73(21): 6448-6461, 2013

Acquired resistance to BRAF inhibition induces epithelial-to-mesenchymal transition in BRAF (V600E) mutant thyroid cancer by c-Met-mediated AKT activation. Oncotarget 8(1): 596-609, 2017

Copper Chelation Inhibits BRAF V600E -Driven Melanomagenesis and Counters Resistance to BRAF V600E and MEK1/2 Inhibitors. Cancer Research 77(22): 6240-6252, 2017

Utility of BRAF V600E mutation-specific immunohistochemistry in detecting BRAF V600E-mutated gastrointestinal stromal tumors. American Journal of Clinical Pathology 144(5): 782-789, 2015

Molecular pathways: response and resistance to BRAF and MEK inhibitors in BRAF(V600E) tumors. Clinical Cancer Research 20(5): 1074-1080, 2014

Induction of Resistance to BRAF Inhibitor Is Associated with the Inability of Spry2 to Inhibit BRAF-V600E Activity in BRAF Mutant Cells. Biomolecules and Therapeutics 23(4): 320-326, 2015

Anticancer effects of combinational treatment with BRAF V600E siRNA and PI3K pathway inhibitors in melanoma cell lines harboring BRAF V600E. Oncology Letters 16(1): 632-642, 2018

Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF V600E -Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clinical Cancer Research 25(15): 4749-4760, 2019

Luminal expression of PIK3CA mutant H1047R in the mammary gland induces heterogeneous tumors. Cancer Research 71(13): 4344-4351, 2011

Pathological complete response induced by neoadjuvant treatment using BRAF and MEK inhibitors in a patient with unresectable BRAF V600E-mutant malignant melanoma of the gallbladder. Oncotargets and Therapy 11: 8723-8728, 2018

BRAF-V600E mutant papillary craniopharyngioma dramatically responds to combination BRAF and MEK inhibitors. Cns Oncology 6(2): 95-99, 2017

Rare-05. Braf-V600E Mutant Papillary Craniopharyngioma Dramatically Responds To Combination Braf And Mek Inhibitors. Neuro-Oncology 18(Suppl_6): vi162, 2016

BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery 2018: 8782328, 2018

Combination Treatment with the BRAF V600E Inhibitor Vemurafenib and the BH3 Mimetic Navitoclax for BRAF-Mutant Thyroid Carcinoma. Thyroid 29(4): 540-548, 2019

BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. Journal of Clinical Endocrinology and Metabolism 92(6): 2264-2271, 2007